Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment)
Awards & highlights
Study Summary
This trial is testing a new drug called NM32-2668 in adult patients with advanced solid tumors. The main goals are to check the safety and effectiveness of the drug, find the highest safe dose
Who is the study for?
Adults with certain advanced solid tumors, including various cancers like endometrial, melanoma, ovarian, kidney, breast cancer and more. Participants must meet specific health criteria to join.Check my eligibility
What is being tested?
NM32-2668 is being tested for safety and effectiveness in treating selected advanced solid tumors. This early-phase trial will determine the best dose and gather initial data on how well it works.See study design
What are the potential side effects?
Since this is a first-in-human study of NM32-2668, potential side effects are not yet fully known but may include typical drug reactions such as nausea, fatigue, or allergic responses.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Duration of dose interruptions/reductions
Frequency of dose interruptions/reductions
Incidence of Dose Limiting Toxicities (DLTs)
+1 moreSecondary outcome measures
Assessment of accumulation ratios of AUC (ARauc) of NM32-2668 in serum
Assessment of accumulation ratios of Cmax (ARcmax) of NM32-2668 in serum
Assessment of accumulation ratios of Cmin (ARcmin) of NM32-2668 in serum
+19 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: NM32-2668Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Numab Therapeutics AGLead Sponsor
2 Previous Clinical Trials
192 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has NM32-2668 received approval from the FDA?
"As a Phase 1 trial, the safety rating for NM32-2668 from our team at Power is designated as 1 due to the scarcity of corroborating data regarding its safety and effectiveness."
Answered by AI
Is this medical study currently open for enrollment?
"As per clinicaltrials.gov, this investigation is currently in the process of recruiting suitable participants. The original posting date for this research was 29th March 2024, with the most recent update made on 1st March 2024."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger